Typhim Vi Generic Name & Formulations
Multidose vial (20 doses)—1
Store at 2° to 8°C (35° to 46°F); do not freeze.
Mechanism of Action
Typhim Vi Indications
Typhim Vi Dosage and Administration
Prior to Treatment Evaluations
Typhim Vi vaccine is not indicated for routine immunization of individuals in the United States.
Selective immunization against typhoid fever is recommended under the following circumstances:
- Travelers to areas where a recognized risk of exposure to typhoid exists, particularly ones who will have prolonged exposure to potentially contaminated food and water.
- Persons with intimate exposure (ie, continued household contact) to a documented typhoid carrier.
- Workers in microbiology laboratories who frequently work with S typhi.
For intramuscular use only.
- Adults: Administer in the deltoid.
- Children: Administer in the deltoid or the anterolateral thigh.
Immunization with Typhim Vi vaccine should occur at least 2 weeks prior to expected exposure to S typhi.
Typhim Vi Contraindications
Typhim Vi Boxed Warnings
Typhim Vi Warnings/Precautions
Have epinephrine (1:1000) inj available. Immunocompromised states: immune response may be suboptimal. Previous typhoid vaccination. Acute infection, active febrile illness: may consider delaying vaccination unless withholding entails a greater risk. Syncope possible following vaccination. Exposure to contaminated food and water should be avoided. Pregnancy. Nursing mothers.
Only administer to pregnant women if clearly needed; no data available on fetal harm or reproduction capacity.
Nursing Mother Considerations
No data available on use in nursing mothers; use caution. It is not known whether Typhim Vi vaccine is excreted in human milk.
Safety and effectiveness have not been established in children under 2 years of age.
Typhim Vi Pharmacokinetics
Typhim Vi Interactions
Concomitant corticosteroids, alkylating drugs, antimetabolites, radiation: may get suboptimal immune response. Do not mix with any vaccine in the same syringe.
Typhim Vi Adverse Reactions
Typhim Vi Clinical Trials
A randomized double-blind controlled trial with Typhim Vi vaccine (liquid formulation) was conducted in 5 villages west of Kathmandu, Nepal.
- 3454 received Typhim Vi; 3454 in the control group received 23-valent pneumococcal polysaccharide vaccine.
- Study included 6439 individuals 5 to 44 years old, 165 children 2 to 4 years old and 304 adults over 44 years old.
- Overall protective efficacy of Typhim Vi vaccine was 74% (95% CI, 49-87) for blood culture confirmed cases of typhoid fever during 20 months of post-vaccination follow-up.
The protective efficacy of the Typhoid Vi Polysaccharide Vaccine, lyophilized formulation, was evaluated in a randomized double-blind controlled trial conducted in South Africa.
- 5692 children received Vi capsular polysaccharide vaccine; 5692 in the control group received meningococcal polysaccharide (Groups A+C) vaccine.
- The protective efficacy for the Vi capsular polysaccharide (lyophilized formulation) group for blood culture confirmed cases of typhoid fever was 55% (95% CI, 30-70) overall during 3 years of post-vaccination follow-up, and was 61%, 52% and 50%, respectively, for years 1, 2, and 3.
Efficacy studies were not feasible in a US population because of the low incidence of typhoid fever. Immunogenicity and safety trials were conducted in an adult US population. A single dose of Typhim Vi vaccine induced a 4-fold or greater increase in antibody levels in 88% and 96% of this adult population for 2 studies, respectively, following vaccination.
Concurrently Administered Vaccines
- Double-blind, randomized, controlled clinical trial.
- 945 participants aged 18 through 55 years.
- Study participants received Typhim Vi and Menactra vaccines concomitantly (n=469), or Typhim Vi vaccine followed 1 month later by Menactra vaccine (n=476).
- Sera were obtained approximately 28 days after each respective vaccination.
- Antibody response to Typhim Vi vaccine and to Menactra vaccine components were similar between groups.
Typhim Vi Note
Typhim Vi Patient Counseling
Vaccination may not protect 100% of individuals. Travelers should take precautions to avoid contact with or ingestion of contaminated food and water.